La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GSK Salute del bilancio

Salute finanziaria criteri di controllo 3/6

GSK ha un patrimonio netto totale di £13.8B e un debito totale di £16.9B, che porta il suo rapporto debito/patrimonio netto a 123%. Le sue attività totali e le sue passività totali sono rispettivamente £58.1B e £44.3B. L'EBIT di GSK è £9.0B rendendo il suo rapporto di copertura degli interessi 16. Ha liquidità e investimenti a breve termine pari a £3.0B.

Informazioni chiave

123.0%

Rapporto debito/patrimonio netto

UK£16.94b

Debito

Indice di copertura degli interessi	16x
Contanti	UK£2.98b
Patrimonio netto	UK£13.77b
Totale passività	UK£44.30b
Totale attività	UK£58.07b

Aggiornamenti recenti sulla salute finanziaria

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Jan 17

Recent updates

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Aug 05

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { GSK di £16.8B ) non coprono le sue passività a breve termine ( £20.3B ).

Passività a lungo termine: Le attività a breve termine di GSK ( £16.8B ) non coprono le sue passività a lungo termine ( £24.0B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 101.4% ) di GSK è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di GSK si è ridotto da 1127.7% a 123% negli ultimi 5 anni.

Copertura del debito: Il debito di GSK è ben coperto dal flusso di cassa operativo ( 44.1% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di GSK sono ben coperti dall'EBIT ( 16 x copertura).

GSK Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Recent updates

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane